Marie Mazur is a Global Commercial Executive with a proven track record of successfully growing revenue and profits for major vaccine and pharmaceutical companies.

Through December 2019, she headed up the Pandemic Response Solutions unit for Seqirus, a CSL Company. During her tenure, Seqirus became the global market leader in pandemic vaccine response. In her prior role as president of the bioCSL unit, Marie led the commercial due diligence effort that resulted in the Novartis Influenza Business acquisition. Seqirus is now the only vaccine company focused on the prevention of seasonal and pandemic influenza.

In 2018-2019, Marie was Co-Chair of BDPAC, the Biodefense Policy Advisory Committee at the Biotechnology Innovation Organization.

Prior to joining CSL, Marie held successive global commercial leadership positions at Sanofi Pasteur, 3M Pharmaceuticals and GlaxoSmithKline Biologicals, in Europe and in the United States.

Marie received her doctorate in Pharmacy, and her master’s degree in Regulatory Affairs, from Paris University in France. She is also a graduate from INSEAD Business School.

Marie brings 20 years of seasonal and pandemic influenza vaccine industry experience and is known for her relentless support to PIVI since the program inception in 2013. In 2015, Marie was awarded a special recognition for Exemplary Leadership, Compassion, Commitment to and Support for the Partnership for Influenza Vaccine Introduction.